Heron Therapeutics, Inc.
HRTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000818033
No open-market purchases or sales by Heron Therapeutics, Inc. insiders were filed in the last 90 days; 163 institutions reported holding it in 13F filings for Q2 2026, worth $57.1M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:12 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $20.2M (13.0% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Mar 12, 2024 | Jan 9, 2023 | Feb 28, 2022 |
| Revenue | $154.9M | $144.3M | $127.0M | $107.7M | $86.3M |
| Cost of revenue | $41.3M | $38.6M | $65.1M | $54.9M | $46.0M |
| Gross profit | $113.6M | $105.6M | $61.9M | – | – |
| Research and development | $12.4M | $16.7M | $55.9M | $107.5M | $130.8M |
| Selling, general and administrative | $54.6M | $53.4M | $49.0M | $37.4M | $40.2M |
| Operating income | -$2.54M | -$11.5M | -$110.6M | -$174.7M | -$217.8M |
| Interest expense | – | – | $3.87M | $2.47M | $2.41M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$20.2M | -$13.6M | -$110.6M | -$182.0M | -$220.7M |
| EPS, basic | $-0.12 | $-0.09 | $-0.80 | $-1.67 | – |
| EPS, diluted | $-0.12 | $-0.09 | $-0.80 | $-1.67 | – |
| Weighted shares, basic | 166.7M | 152.4M | 138.1M | 108.9K | – |
| Weighted shares, diluted | 166.7M | 152.4M | 138.1M | 108.9K | – |
| Margins and growth | |||||
| Gross margin | 73.3% | 73.2% | 48.8% | – | – |
| Operating margin | -1.6% | -8.0% | -87.1% | -162.2% | -252.3% |
| Net margin | -13.0% | -9.4% | -87.0% | -169.1% | -255.6% |
| Revenue growth, year over year | +7.4% | +13.6% | +18.0% | +24.7% | −2.6% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Mar 12, 2024 | Jan 9, 2023 | Feb 28, 2022 |
| Cash and equivalents | $28.6M | $25.8M | $28.7M | $15.4M | $90.5M |
| Accounts receivable | $89.6M | $78.9M | $60.1M | $52.0M | $35.5M |
| Inventory | $92.7M | $53.2M | $42.1M | $54.6M | $48.4M |
| Total current assets | $238.1M | $209.0M | $188.8M | $205.4M | $254.4M |
| Property, plant and equipment | $12.4M | $14.9M | $20.2M | $22.2M | $23.7M |
| Total assets | $255.9M | $233.1M | $222.5M | $251.0M | $305.7M |
| Accounts payable | $8.99M | $11.7M | $3.24M | $3.23M | $3.80M |
| Total current liabilities | $96.1M | $91.5M | $79.7M | $82.4M | $71.1M |
| Total liabilities | $241.5M | $266.8M | $256.5M | $237.4M | $228.1M |
| Shareholders' equity | $14.3M | -$33.7M | -$34.0M | $13.6M | $77.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Mar 12, 2024 | Jan 9, 2023 | Feb 28, 2022 |
| Operating cash flow | -$27.6M | -$22.5M | -$58.8M | -$146.9M | -$203.4M |
| Capital expenditures | $317.0K | $1.71M | $1.54M | $1.82M | $3.02M |
| Free cash flow | -$27.9M | -$24.2M | -$60.3M | -$148.7M | -$206.4M |
| Depreciation and amortization | $2.31M | $2.49M | $2.90M | $2.89M | $3.02M |
| Stock-based compensation | $10.3M | $13.0M | $32.9M | $43.0M | $46.9M |
| Investing cash flow | $16.0M | $18.7M | $18.0M | -$3.32M | $32.7M |
| Financing cash flow | $14.4M | $940.0K | $54.1M | $75.1M | $156.0M |
| Net change in cash | $2.85M | -$2.88M | $13.3M | -$75.2M | -$14.6M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 6.7% | 9.0% | 25.9% | 39.9% | 54.3% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 4, 2026 | 190.3M | +3.8% | SEC |
| Aug 5, 2026 | 189.9M | +23.9% | SEC |
| May 6, 2026 | 189.3M | +24.1% | SEC |
| Feb 13, 2026 | 188.5M | +23.8% | SEC |
| Oct 30, 2025 | 183.4M | +20.6% | SEC |
| Jul 31, 2025 | 153.3M | +1.1% | SEC |
| May 1, 2025 | 152.6M | +1.3% | SEC |
| Feb 13, 2025 | 152.3M | +1.3% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.